

1 Amend printed bill, page 7, line 13, strike "**authorization.**" and substitute  
2 "**authorization - study - repeal.**".

3 Page 7, line 13, strike "A" and substitute "(1) A".

4 Page 7, strike lines 17 and 18 and substitute "drug.

5 (2) BEFORE JULY 1, 2027, A CARRIER SHALL NOT REQUIRE A  
6 COVERED PERSON TO UNDERGO STEP THERAPY OR TO RECEIVE PRIOR  
7 AUTHORIZATION BEFORE A PROVIDER MAY, ACTING WITHIN THE  
8 PROVIDER'S SCOPE OF PRACTICE, PRESCRIBE OR DISPENSE ANY DRUG  
9 APPROVED BY THE FDA AND USED FOR THE TREATMENT OR PREVENTION  
10 OF HIV THAT IS INCLUDED ON THE CARRIER'S PRESCRIPTION DRUG  
11 FORMULARY AS OF MARCH 1, 2023.

12 (3) (a) THE DIVISION SHALL CONTRACT WITH ONE OR MORE  
13 ENTITIES TO CONDUCT A STUDY THAT INCLUDES QUALITATIVE PATIENT  
14 AND PROVIDER EXPERIENCE INFORMATION AND AN ACTUARIAL REVIEW TO  
15 CONSIDER THE PREDICTED COST AND HEALTH IMPACTS OF REMOVING THE  
16 REQUIREMENT FOR A COVERED PERSON TO UNDERGO STEP THERAPY OR TO  
17 RECEIVE PRIOR AUTHORIZATION BEFORE A PROVIDER MAY, ACTING WITHIN  
18 THE PROVIDER'S SCOPE OF PRACTICE, PRESCRIBE OR DISPENSE A DRUG FOR  
19 THE TREATMENT OF HIV. IN CONDUCTING THE STUDY, THE ENTITY  
20 CONTRACTED TO PERFORM THE STUDY MUST CONSULT WITH COMMUNITY  
21 ORGANIZATIONS LED BY PEOPLE LIVING WITH HIV. THE DIVISION SHALL  
22 PROVIDE THE COMPLETED STUDY TO THE GENERAL ASSEMBLY NO LATER  
23 THAN OCTOBER 1, 2026.

24 (b) THIS SUBSECTION (3) IS REPEALED, EFFECTIVE JULY 1, 2027.".

\*\*\* \* \* \* \*